Drug Approval | March 21, 2022
USFDA approves Perrigo’s Nasonex
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Spread over 43,000 square feet, the facility will be set up to cater to the increasing demand for transformative molecular testing in India and across the world for early and accurate diagnosis
In contrast to the digital health solutions in the market, TEngage is cloud-based, fully customizable and allows hospitals to implement modules with just the required features, keeping the deployment and operational cost in check
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
Subscribe To Our Newsletter & Stay Updated
